Bedrijfsoverzicht
PROCEPT BioRobotics Corporation is a specialized surgical robotics enterprise dedicated to developing transformative solutions within the field of urology, operating both in the United States and on an international scale. The company focuses on the development, manufacturing, and commercialization of the AquaBeam Robotic System, which functions as an image-guided, surgical robotic platform designed specifically for minimally invasive urologic procedures. This entity operates within the Healthcare sector, specifically categorized under the Medical Devices industry, positioning it at the intersection of advanced technology and critical patient care infrastructure. The company currently maintains a market capitalization of $1.31B, generates annual revenue of $308.05M, and employs a workforce of 888 individuals. These valuation and revenue figures indicate that PROCEPT BioRobotics Corporation has achieved a significant market presence, suggesting a substantial scale of operations that requires considerable capital investment in research, development, and manufacturing facilities to sustain its growth trajectory in a competitive medical technology landscape.
Financiële gezondheid
The company reported a revenue of $308.05M over the trailing twelve months, yet recorded a net income of $-95,572,000 and an EBITDA of $-97,469,000, revealing a substantial gap between top-line generation and bottom-line profitability. This disparity highlights a cost structure where operating expenses and research expenditures significantly outweigh current earnings, resulting in a profit margin of -31.0% and an operating margin of -40.6%. While the gross margin stands at a robust 63.7%, indicating high value added per unit sold, the negative operating and profit margins demonstrate that overhead costs and sales expenses are consuming the majority of gross profits. Free cash flow stands at $-23,916,124, which reflects a burn rate typical for high-growth medical device companies investing heavily in technology expansion rather than immediate cash generation. Despite these outflows, the company holds a cash reserve of $286.50M against total debt of $78.48M, creating a conservative balance sheet that provides ample liquidity to fund operations without immediate external financing. The debt-to-equity ratio of 21.45 suggests a leveraged capital structure, yet the high cash position mitigates immediate solvency risks. Furthermore, a current ratio of 6.84 indicates exceptional short-term liquidity, meaning the company possesses more than six times the current assets necessary to cover its short-term obligations. Return on Equity is -24.9% and Return on Assets is -12.5%, metrics that reveal that management is currently prioritizing growth and market share acquisition over immediate profit maximization, a common strategy in the early-to-mid stages of a medical device lifecycle.
Waarderingsbeoordeling
The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to negative earnings, while the forward P/E is calculated at -26.27. The absence of a positive trailing P/E implies that the market is pricing the stock based on future expectations rather than historical profitability, suggesting investors anticipate a turnaround in earnings trajectory in the coming quarters. The price-to-book ratio is 3.57, indicating that the market is valuing the company at a significant premium over its book value, likely reflecting the intangible value of its proprietary robotics technology and intellectual property. Alternative valuation metrics such as the price-to-sales ratio of 4.25 and the EV/EBITDA of -11.29 further suggest that the market is willing to pay a high multiple for revenue growth, betting on the scalability of the AquaBeam system. In terms of price momentum, the stock has a 52-week high of $66.85 and a 52-week low of $19.35, providing a clear range within which the security trades. The beta of 0.93 indicates that the stock's price volatility closely mirrors that of the broader market, suggesting it does not exhibit extreme sensitivity to general market swings compared to higher-beta biotech stocks.
Growth & Income
The company demonstrates a revenue growth rate of 11.9% year-over-year, whereas earnings growth is N/A due to the company's current unprofitable status. This divergence implies that the business is expanding its top line rapidly, but profitability has not yet caught up, a pattern typical for capital-intensive manufacturing firms scaling up production and distribution networks. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company retains all of its earnings to reinvest into research, development, and the expansion of its surgical robotics portfolio rather than distributing cash to shareholders. This reinvestment strategy is consistent with the growth profile of a medical device firm that must continuously innovate to maintain its competitive edge in the urology sector. The overall growth and income profile is characterized by strong top-line expansion funded by a robust cash position, with no reliance on dividend income for shareholder returns.